指南与共识呼吸道感染

阿莫西林/克拉维酸作为抗生素管理的基石:整合WHO AWaRe原则、意大利建议与循证实践

Amoxicillin/clavulanate as a cornerstone of antibiotic stewardship: integrating WHO AWaRe principles, Italian recommendations, and evidence-based practice
RSS 订阅 · 指南共识 · 肺炎 · 2025-10-07

本文为专家意见,综述阿莫西林/克拉维酸在抗生素管理框架中的定位,整合WHO AWaRe分类、意大利管理建议及随机对照试验与荟萃分析证据。该药属Access组,对流感嗜血杆菌、卡他莫拉菌等呼吸道病原体有广谱活性,在急性细菌性鼻窦炎、中耳炎、社区获得性肺炎及慢性支气管炎急性加重中显示高细菌清除率与临床治愈率。

要点

  • 阿莫西林/克拉维酸属WHO AWaRe的Access组,为常见社区获得性感染的一线选择。
  • 对产β-内酰胺酶的流感嗜血杆菌和卡他莫拉菌仍保持活性。
  • 强调短疗程、针对性处方,避免用于病毒性综合征。

核心结论

  • 阿莫西林/克拉维酸与抗生素管理原则一致,是优化治疗结局并减缓耐药性的循证策略。

研究设计与样本

  • 专家意见类文章,综述药理学特征、临床证据及其在意大利与全球背景下的相关性。

主要发现

  • 随机对照试验与荟萃分析显示,该药在急性细菌性鼻窦炎、中耳炎、社区获得性肺炎及慢性支气管炎急性加重中细菌清除率和临床治愈率均较高。
  • 在儿童迁延性细菌性支气管炎和慢性湿咳中显示显著疗效。
  • 对照数据表明其疗效不劣于或优于大环内酯类和氟喹诺酮类,且耐药选择潜能更低、耐受性良好。

关键数值与推荐

  • WHO AWaRe分类将该药纳入Access组,即疗效确切、耐药潜能低的窄谱药物。
  • 国际与各国指南将其列为常见社区获得性感染的一线选择。
  • 管理建议强调短疗程治疗、针对性处方,并避免用于病毒性综合征。

临床怎么用

  • 在社区获得性呼吸道感染中,可按指南将其作为一线经验性选择,并遵循短疗程与针对性用药原则。

局限性

  • 本文为专家意见,非系统评价或原始研究,未报告具体样本量、效应量或P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Minerva Med. 2025 Dec;116(6):497-503. doi: 10.23736/S0026-4806.25.09808-8. Epub 2025 Oct 7. ABSTRACT Antimicrobial resistance (AMR) remains a critical global health concern, largely driven by inappropriate antibiotic use. To address this challenge, the World Health Organization (WHO) developed the AWaRe (Access, Watch, Reserve) classification, prioritizing the use of Access antibiotics - narrow-spectrum agents with proven efficacy and low resistance potential. Amoxicillin/clavulanate, included in the Access group, is widely endorsed in international and national guidelines, as a first-line option for common community-acquired infections. This Expert Opinion reviews the positioning of amoxicillin/clavulanate within stewardship frameworks, synthesizing its pharmacological characteristics, clinical evidence, and relevance in both Italian and global contexts. The combination of amoxicillin with the β-lactamase inhibitor clavulanic acid provides broad activity against key respiratory pathogens such as Haemophilus influenzae, and Moraxella catarrhalis, including β-lactamase-producing strains. Evidence from randomized controlled trials and meta-analyses demonstrates high bacteriological eradication and clinical cure rates across acute bacterial rhinosinusitis, otitis media, community-acquired pneumonia, and chronic bronchitis exacerbations. In pediatric populations, amoxicillin/clavulanate has shown significant efficacy in protracted bacterial bronchitis and chronic wet cough. Comparative data confirm its equivalence or superiority to macrolides and fluoroquinolones while maintaining a lower resistance selection potential and favorable tolerability. The integration of WHO AWaRe targets, Italian stewardship recommendations, and robust clinical evidence underscores the central role of amoxicillin/clavulanate in rational antibiotic prescribing. Its stewardship-aligned use - emphasizing short-course therapy, targeted prescribing, and avoidance in viral syndromes - represents a pragmatic and evidence-based strategy to optimize treatment outcomes while contributing to AMR mitigation in both national and global contexts. PMID: 41054784 | DOI: 10.23736/S0026-4806.25.09808-8

来源:指南共识 · 肺炎,查看原文。版权归原作者所有。

引用

  1. 指南共识 · 肺炎:Amoxicillin/clavulanate as a cornerstone of antibiotic stewardship: integrating WHO AWaRe principles, Italian recommendations, and evidence-based practice

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。